S Yousuf Zafar

Summary

Affiliation: Duke University Medical Center
Country: USA

Publications

  1. doi request reprint Decision making and quality of life in the treatment of cancer: a review
    S Yousuf Zafar
    Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    Support Care Cancer 17:117-27. 2009
  2. pmc Capecitabine in the management of colorectal cancer
    Bradford R Hirsch
    Division of Medical Oncology, Duke University Medical Center, Durham, NC, USA
    Cancer Manag Res 3:79-89. 2011
  3. pmc The financial toxicity of cancer treatment: a pilot study assessing out-of-pocket expenses and the insured cancer patient's experience
    S Yousuf Zafar
    Center for Learning Health Care, Duke Clinical Research Institute, Duke Cancer Institute, Durham, North Carolina 27710, USA
    Oncologist 18:381-90. 2013
  4. pmc Chemotherapy use and patient treatment preferences in advanced colorectal cancer: a prospective cohort study
    S Yousuf Zafar
    Duke Cancer Institute, Durham, North Carolina 27710, USA
    Cancer 119:854-62. 2013
  5. doi request reprint Consensus-based standards for best supportive care in clinical trials in advanced cancer
    S Yousuf Zafar
    Division of Medical Oncology, Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    Lancet Oncol 13:e77-82. 2012
  6. ncbi request reprint Malignancy after solid organ transplantation: an overview
    S Yousuf Zafar
    Divisions of Hematology and Medical Oncology, Duke University Medical Center, 508 Fulton Street 152, Durham, North Carolina 27705, USA
    Oncologist 13:769-78. 2008
  7. pmc Early dissemination of bevacizumab for advanced colorectal cancer: a prospective cohort study
    S Yousuf Zafar
    Division of Medical Oncology, Department of Medicine, Duke University Medical Center, Durham, NC, USA
    BMC Cancer 11:354. 2011
  8. doi request reprint Standards for palliative care delivery in oncology settings
    S Yousuf Zafar
    Division of Medical Oncology, Department of Medicine, Duke University Medical Center, Durham, NC 27701, USA
    Cancer J 16:436-43. 2010
  9. ncbi request reprint Treatment-related toxicity and supportive care in metastatic colorectal cancer
    S Yousuf Zafar
    Division of Medical Oncology, Department of Medicine, Duke University Medical Center, 2424 Erwin Road, Suite G05, Hock Plaza, DUMC Box 2732, Durham, NC 27710, USA
    J Support Oncol 8:15-20. 2010
  10. pmc Comorbidity, age, race and stage at diagnosis in colorectal cancer: a retrospective, parallel analysis of two health systems
    S Yousuf Zafar
    Department of Medicine, Duke University Medical Center, Durham, USA
    BMC Cancer 8:345. 2008

Detail Information

Publications32

  1. doi request reprint Decision making and quality of life in the treatment of cancer: a review
    S Yousuf Zafar
    Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    Support Care Cancer 17:117-27. 2009
    ..Although these factors are important, physicians are often unable to effectively judge their patients' preferences. Patients are often unable to fully understand their prognoses and the treatment intent...
  2. pmc Capecitabine in the management of colorectal cancer
    Bradford R Hirsch
    Division of Medical Oncology, Duke University Medical Center, Durham, NC, USA
    Cancer Manag Res 3:79-89. 2011
    ..The purpose of this review is to synthesize the literature in a fashion that can be used to help guide decisions. In a setting of increasing focus on cost, the pharmacoeconomic literature is also briefly reviewed...
  3. pmc The financial toxicity of cancer treatment: a pilot study assessing out-of-pocket expenses and the insured cancer patient's experience
    S Yousuf Zafar
    Center for Learning Health Care, Duke Clinical Research Institute, Duke Cancer Institute, Durham, North Carolina 27710, USA
    Oncologist 18:381-90. 2013
    ..Our objective was to describe experiences of insured cancer patients requesting copayment assistance and to describe the impact of health care expenses on well-being and treatment...
  4. pmc Chemotherapy use and patient treatment preferences in advanced colorectal cancer: a prospective cohort study
    S Yousuf Zafar
    Duke Cancer Institute, Durham, North Carolina 27710, USA
    Cancer 119:854-62. 2013
    ..The objective of this study was to determine how patient preferences guide the course of palliative chemotherapy for advanced colorectal cancer...
  5. doi request reprint Consensus-based standards for best supportive care in clinical trials in advanced cancer
    S Yousuf Zafar
    Division of Medical Oncology, Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    Lancet Oncol 13:e77-82. 2012
    ..Availability of resources was cited as a challenge to implementation of best supportive care standards...
  6. ncbi request reprint Malignancy after solid organ transplantation: an overview
    S Yousuf Zafar
    Divisions of Hematology and Medical Oncology, Duke University Medical Center, 508 Fulton Street 152, Durham, North Carolina 27705, USA
    Oncologist 13:769-78. 2008
    ..Treatment involves modification of the immunosuppressive drug regimen, resection of localized disease, and chemotherapy. We present the second reported case of a patient with lung transplantation who developed KS in the lung graft...
  7. pmc Early dissemination of bevacizumab for advanced colorectal cancer: a prospective cohort study
    S Yousuf Zafar
    Division of Medical Oncology, Department of Medicine, Duke University Medical Center, Durham, NC, USA
    BMC Cancer 11:354. 2011
    ..We describe early dissemination patterns for first-line bevacizumab given for metastatic colorectal cancer treatment...
  8. doi request reprint Standards for palliative care delivery in oncology settings
    S Yousuf Zafar
    Division of Medical Oncology, Department of Medicine, Duke University Medical Center, Durham, NC 27701, USA
    Cancer J 16:436-43. 2010
    ..Guideline efficacy has not been evaluated, and their dissemination into standard care has been poor. A conceptual framework for better implementation of existing guidelines might improve usage and outcomes...
  9. ncbi request reprint Treatment-related toxicity and supportive care in metastatic colorectal cancer
    S Yousuf Zafar
    Division of Medical Oncology, Department of Medicine, Duke University Medical Center, 2424 Erwin Road, Suite G05, Hock Plaza, DUMC Box 2732, Durham, NC 27710, USA
    J Support Oncol 8:15-20. 2010
    ..These data, obtained from a usual-practice setting, provide benchmarks to improve clinical practice...
  10. pmc Comorbidity, age, race and stage at diagnosis in colorectal cancer: a retrospective, parallel analysis of two health systems
    S Yousuf Zafar
    Department of Medicine, Duke University Medical Center, Durham, USA
    BMC Cancer 8:345. 2008
    ..The objective of this study is to investigate how comorbidity, race and age influence stage of CRC diagnosis...
  11. pmc A phase II study of capecitabine, oxaliplatin, and bevacizumab in the treatment of metastatic esophagogastric adenocarcinomas
    Hope E Uronis
    Duke Cancer Institute, Durham, North Carolina 27710, USA
    Oncologist 18:271-2. 2013
    ..We evaluated the safety, tolerability, and efficacy of the combination capecitabine, oxaliplatin, and bevacizumab in the treatment of metastatic esophagogastric adenocarcinomas...
  12. pmc Phase I study of bevacizumab, everolimus, and panobinostat (LBH-589) in advanced solid tumors
    John H Strickler
    Duke University Medical Center, Durham, NC 27710, USA
    Cancer Chemother Pharmacol 70:251-8. 2012
    ..To define the maximum tolerated dose, clinical toxicities, and pharmacodynamics of bevacizumab, everolimus, and panobinostat (LBH-589) when administered in combination to patients with advanced solid tumor malignancies...
  13. pmc A phase II trial of bevacizumab plus everolimus for patients with refractory metastatic colorectal cancer
    Ivy Altomare
    Duke University Medical Center, Durham, North Carolina, USA
    Oncologist 16:1131-7. 2011
    ..A phase I study of bevacizumab plus everolimus demonstrated that the combination is safe; activity was seen in several patients with refractory mCRC...
  14. pmc Using NCCN clinical practice guidelines in oncology to measure the quality of colorectal cancer care in the veterans health administration
    George L Jackson
    Durham Veterans Affairs Medical Center, Center for Health Services Research in Primary Care, Durham, North Carolina 27705, USA
    J Natl Compr Canc Netw 11:431-41. 2013
    ..NCCN Clinical Practice Guidelines in Oncology were successfully used to develop a measurement system for a VHA research-operations quality improvement partnership...
  15. ncbi request reprint Electronic patient-reported data capture as a foundation of rapid learning cancer care
    Amy P Abernethy
    Division of Medical Oncology, Department of Medicine, Duke University Health System, Duke University Medical Center DUMC, Durham, NC 27710, USA
    Med Care 48:S32-8. 2010
    ....
  16. pmc A phase I study of bevacizumab, everolimus and panitumumab in advanced solid tumors
    Gordana Vlahovic
    Duke University Medical Center, Seeley G Mudd Bldg, 10 Bryan Searle Drive, Box 3052, Durham, NC 27710, USA
    Cancer Chemother Pharmacol 70:95-102. 2012
    ..This study evaluated the maximum tolerated dose/recommended phase II dose and safety and tolerability of bevacizumab, everolimus and panitumumab drug combination...
  17. pmc Longitudinal patterns of chemotherapy use in metastatic colorectal cancer
    S Yousuf Zafar
    Cancer Center Biostatistics Division of Medical Oncology, Department of Medicine and Department of Biostatistics and Bioinformatics, Duke University Medical Center, Durham, NC
    J Oncol Pract 5:228-33. 2009
    ....
  18. pmc Quality of nonmetastatic colorectal cancer care in the Department of Veterans Affairs
    George L Jackson
    Durham Veterans Affairs Medical Center, Durham, NC 27705, USA
    J Clin Oncol 28:3176-81. 2010
    ..We measured the quality of nonmetastatic colorectal cancer (CRC) care in VA as indicated by concordance with National Comprehensive Cancer Network practice guidelines (six indicators) and timeliness of care (three indicators)...
  19. pmc Management of gastrointestinal symptoms in advanced cancer patients: the rapid learning cancer clinic model
    Amy P Abernethy
    Department of Medicine, Division of Medical Oncology, Duke University Medical Center, Durham, North Carolina 27710, USA
    Curr Opin Support Palliat Care 4:36-45. 2010
    ....
  20. doi request reprint Quality management of potential chemotherapy-induced neutropenic complications: evaluation of practice in an academic medical center
    Amy P Abernethy
    Department of Medicine, Division of Medical Oncology, Duke University Medical Center DUMC, Box 3436, Durham, NC 27710, USA
    Support Care Cancer 17:735-44. 2009
    ..How frequently does care at our institution conform to established guidelines?..
  21. pmc A phase I study of bevacizumab (B) in combination with everolimus (E) and erlotinib (E) in advanced cancer (BEE)
    Karen E Bullock
    Duke University Medical Center, Seeley G Mudd Bldg, 10 Bryan Searle Drive, Box 3052, Durham, NC 27710, USA
    Cancer Chemother Pharmacol 67:465-74. 2011
    ..This study evaluated the safety, tolerability, and pharmacokinetics of bevacizumab, everolimus, and erlotinib combination...
  22. ncbi request reprint Use of tablet personal computers for sensitive patient-reported information
    Alexandra Dupont
    Department of Medicine, Division of Medical Oncology, Duke University Medical Center, Durham, North Carolina, USA
    J Support Oncol 7:91-7. 2009
    ..The e/Tablet electronic system may provide a "safer" environment than paper questionnaires for cancer patients to answer private or highly personal questions on sensitive topics such as sexuality...
  23. doi request reprint Detailing of gastrointestinal symptoms in cancer patients with advanced disease: new methodologies, new insights, and a proposed approach
    Amy P Abernethy
    Department of Medicine, Division of Medical Oncology, Duke University Medical Center, Durham, North Carolina 27710, USA
    Curr Opin Support Palliat Care 3:41-9. 2009
    ....
  24. ncbi request reprint A decision exercise to engage cancer patients and families in Deliberation about Medicare Coverage for advanced Cancer Care
    Marion Danis
    Sanford School of Public Policy, Duke University, Box 90253, Durham, NC 27708, USA
    BMC Health Serv Res 14:315. 2014
    ..We designed and evaluated a decision exercise that allowed cancer patients and family members to choose Medicare benefits for advanced cancer patients...
  25. ncbi request reprint Phase I study of capecitabine, oxaliplatin, bevacizumab, and everolimus in advanced solid tumors
    Fatima Rangwala
    Duke University Medical Center, Seeley G Mudd Bldg 10 Bryan Searle Drive, Box 3052, Durham, NC, 27710, USA
    Invest New Drugs 32:700-9. 2014
    ..MTD was: everolimus 5 mg daily; capecitabine 680 mg/m(2) BID days 1-14; oxaliplatin 100 mg/m(2) and bevacizumab 7.5 mg/kg, day 1. Activity was noted in mCRC. ..
  26. ncbi request reprint Does comparative effectiveness research promote rationing of cancer care?
    Jeffrey Peppercorn
    Department of Medicine, Division of Medical Oncology, Duke Cancer Institute, Duke University, Durham, NC, USA Electronic address
    Lancet Oncol 15:e132-8. 2014
    ..As we show, all health systems struggle to balance access to cancer care and control of costs; comparative effectiveness data can clarify choices, but does not itself determine policy or promote rationing of care. ..
  27. pmc Self-reported financial burden and satisfaction with care among patients with cancer
    Fumiko Chino
    School of Medicine, Duke Cancer Institute, Sanford School of Public Policy, Department of Bioinformatics and Biostatistics, and Center for Learning Health Care, Duke Clinical Research Institute, Duke University, Durham, North Carolina, USA
    Oncologist 19:414-20. 2014
    ..Health care-related costs and satisfaction are compelling targets for quality improvement in cancer care delivery; however, little is known about how financial burden affects patient satisfaction...
  28. ncbi request reprint Phase I study of dasatinib in combination with capecitabine, oxaliplatin and bevacizumab followed by an expanded cohort in previously untreated metastatic colorectal cancer
    John H Strickler
    Duke University Medical Center, Seeley G Mudd Bldg, 10 Bryan Searle Drive, Box 3052, Durham, NC, 27710, USA
    Invest New Drugs 32:330-9. 2014
    ..We conducted a phase I study of dasatinib, capecitabine, oxaliplatin, and bevacizumab (CapeOx/bevacizumab), with an expansion cohort in metastatic colorectal cancer (CRC)...
  29. pmc Cancer registration needs assessment at a tertiary medical centre in Kilimanjaro, Tanzania
    Leah L Zullig
    Department of Health Policy and Management, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
    World Health Popul 14:12-23. 2013
    ..For most resources, respondents felt that resources were sufficient or attainable. Respondents were generally confident and committed to registry implementation. Lessons learned at KCMC may be more broadly relevant...
  30. ncbi request reprint Carcinoma of the ampulla of Vater: patterns of failure following resection and benefit of chemoradiotherapy
    Manisha Palta
    Department of Radiation Oncology, Duke University Medical Center, Durham, NC, USA
    Ann Surg Oncol 19:1535-40. 2012
    ..Despite radical resection, survival rates remain low with high rates of local failure. We performed a single-institution outcomes analysis to define the role of concurrent chemoradiotherapy (CRT) in addition to surgery...
  31. pmc A strategy to advance the evidence base in palliative medicine: formation of a palliative care research cooperative group
    Amy P Abernethy
    Division of Medical Oncology, Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA
    J Palliat Med 13:1407-13. 2010
    ....
  32. doi request reprint Comparative effectiveness research: moving medical oncology forward
    Bradford R Hirsch
    Duke Cancer Institute, Durham, NC Duke Clinical Research Institute, Durham, NC Electronic address
    Semin Radiat Oncol 24:49-53. 2014
    ..Its true power will lie in linkages to "learning health systems" and real-time application to the day-to-day practice of medicine. ..